HomeA2RR34 • BVMF
add
Arrowhead Pharmaceuticals Inc
Previous close
R$13.75
Year range
R$12.18 - R$22.70
Market cap
2.33B USD
Avg Volume
11.00
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 0.00 | -100.00% |
Operating expense | 162.20M | 30.36% |
Net income | -170.54M | -55.49% |
Net profit margin | — | — |
Earnings per share | -1.37 | -34.31% |
EBITDA | -157.18M | -50.45% |
Effective tax rate | -0.32% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 677.46M | 71.19% |
Total assets | 1.14B | 48.89% |
Total liabilities | 948.74M | 98.32% |
Total equity | 191.06M | — |
Shares outstanding | 124.43M | — |
Price to book | 9.23 | — |
Return on assets | -40.08% | — |
Return on capital | -44.17% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -170.54M | -55.49% |
Cash from operations | -137.22M | -429.26% |
Cash from investing | -222.92M | -830.68% |
Cash from financing | 389.09M | 47,292.08% |
Net change in cash | 33.29M | 498.99% |
Free cash flow | -106.58M | -32.63% |
About
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
609
